Myriad Updates Investors on Companion Dx Deals, EU Expansion, and Capturing Asymptomatic Market
March 10, 2010
Myriad Updates Investors on Companion Dx Deals, EU Expansion, and Capturing Asymptomatic Market
During Myriad's investor day last week, officials disclosed that the firm is working with pharmaceutical companies to develop companion diagnostics for PARP inhibitors and PTEN inhibitors.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Posting 11 Percent Revenue Growth in FY2011, Myriad Focuses on Growing MDx Pipeline
August 10, 2011 / Pharmacogenomics Reporter - Patents, Regulation, Reimbursement: Myriad Reflects on Impact of Key Events on Future Business
November 3, 2010 / Pharmacogenomics Reporter - Continuing Revenue Growth in Third Quarter, Myriad Keeps Focus on Diversifying MDx Product Portfolio
May 8, 2013 / Pharmacogenomics Reporter - Myriad Expects BRACAnalysis to Remain Best Seller in 'Post-Patent' Era
February 6, 2013 / Pharmacogenomics Reporter - Myriad Defends Policy of Urging Docs to Genetically Counsel BRACAnalysis Customers
February 10, 2010 / Pharmacogenomics Reporter